- Subcutaneous nucleic acid therapeutics, involving the administration of RNA- and DNA-based drugs via the subcutaneous route, are emerging as a preferred modality in modern precision medicine due to their improved patient compliance, reduced need for clinical visits, and compatibility with self-administration technologies
- The accelerating demand for these therapeutics is largely driven by the increasing prevalence of genetic disorders, advancements in RNA interference and antisense oligonucleotide platforms, and a growing emphasis on minimally invasive treatment delivery
- North America dominated the subcutaneous nucleic acid therapeutics market with the largest revenue share of 46.1% in 2024, characterized by robust R&D investments, early adoption of genetic medicines, and regulatory support, with the U.S. seeing rapid clinical integration of subcutaneously administered RNA-based therapies for rare and chronic conditions
- Asia-Pacific is expected to be the fastest growing region in the subcutaneous nucleic acid therapeutics market during the forecast period due to expanding healthcare infrastructure, increased funding in genetic research, and rising patient awareness of innovative treatment options
- RNA Interference segment dominated the subcutaneous nucleic acid therapeutics market with a market share of 48.3% in 2024, driven by its successful commercialization of RNAi-based subcutaneous therapies and ongoing clinical advancements targeting a wide range of genetic and metabolic diseases
